25.66
price up icon7.72%   1.84
after-market After Hours: 25.80 0.14 +0.55%
loading
Tourmaline Bio Inc stock is traded at $25.66, with a volume of 199.17K. It is up +7.72% in the last 24 hours and down -3.50% over the past month. Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.
See More
Previous Close:
$23.82
Open:
$24.06
24h Volume:
199.17K
Relative Volume:
0.88
Market Cap:
$628.89M
Revenue:
-
Net Income/Loss:
$11.77M
P/E Ratio:
-165.87
EPS:
-0.1547
Net Cash Flow:
$-19.23M
1W Performance:
+6.92%
1M Performance:
-3.50%
6M Performance:
+90.78%
1Y Performance:
+34.06%
1-Day Range:
Value
$23.82
$26.78
1-Week Range:
Value
$22.21
$26.78
52-Week Range:
Value
$12.12
$48.31

Tourmaline Bio Inc Stock (TRML) Company Profile

Name
Name
Tourmaline Bio Inc
Name
Phone
646-481-9832
Name
Address
27 WEST 24TH STREET, NEW YORK
Name
Employee
74
Name
Twitter
Name
Next Earnings Date
2024-11-12
Name
Latest SEC Filings
Name
TRML's Discussions on Twitter

Compare TRML with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
TRML
Tourmaline Bio Inc
25.66 628.89M 0 11.77M -19.23M -0.1547
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
464.56 119.70B 10.63B -479.80M -1.35B 13.33
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
754.87 82.75B 13.85B 4.65B 3.32B 35.06
Biotechnology icon
ARGX
Argen X Se Adr
614.59 36.73B 1.86B -40.29M -1.28B -4.16
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
253.74 32.53B 2.09B -332.26M 16.06M -4.14
Biotechnology icon
BNTX
Biontech Se Adr
120.72 28.50B 3.30B -501.07M 1.03B 11.54

Tourmaline Bio Inc Stock (TRML) Upgrades & Downgrades

Date Action Analyst Rating Change
Nov-11-24 Reiterated H.C. Wainwright Buy
Dec-15-23 Initiated Jefferies Buy
Dec-04-23 Resumed H.C. Wainwright Buy
Nov-17-23 Initiated Truist Buy
Oct-31-23 Initiated Guggenheim Buy
Oct-25-23 Initiated Piper Sandler Overweight
Oct-20-22 Initiated H.C. Wainwright Buy
Jul-05-22 Downgrade Morgan Stanley Overweight → Equal-Weight
View All

Tourmaline Bio Inc Stock (TRML) Latest News

pulisher
Nov 22, 2024

Jennison Associates LLC Has $29.62 Million Position in Tourmaline Bio, Inc. (NASDAQ:TRML) - MarketBeat

Nov 22, 2024
pulisher
Nov 18, 2024

Prevent Blindness Declares Fifth Annual Thyroid Eye Disease Awareness Week as Nov. 18-24, 2024 - InvisionMag

Nov 18, 2024
pulisher
Nov 17, 2024

This Week in Ophthalmology: Week of November 11, 2024 - Ophthalmology Times

Nov 17, 2024
pulisher
Nov 15, 2024

Blue Owl Capital Holdings LP Adjusts Stake in Tourmaline Bio Inc - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

HC Wainwright Reduces Earnings Estimates for Tourmaline Bio - Defense World

Nov 15, 2024
pulisher
Nov 14, 2024

HC Wainwright Lowers Earnings Estimates for Tourmaline Bio - MarketBeat

Nov 14, 2024
pulisher
Nov 14, 2024

Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024 - The Manila Times

Nov 14, 2024
pulisher
Nov 14, 2024

Tourmaline Bio Sets Key Investor Day with Focus on Pacibekitug Development | TRML Stock News - StockTitan

Nov 14, 2024
pulisher
Nov 14, 2024

Alternus Clean Energy Inc (NASDAQ:ALCE) Sees Significant Decrease in Short Interest - Defense World

Nov 14, 2024
pulisher
Nov 14, 2024

Alchemy Investments Acquisition Corp 1 (NASDAQ:ALCY) Short Interest Update - Defense World

Nov 14, 2024
pulisher
Nov 14, 2024

Short Interest in Alchemy Investments Acquisition Corp 1 (NASDAQ:ALCYW) Decreases By 97.6% - Defense World

Nov 14, 2024
pulisher
Nov 14, 2024

Greenlane Renewables (OTCMKTS:GRNWF) Trading 21.2% Higher – Here’s What Happened - Defense World

Nov 14, 2024
pulisher
Nov 13, 2024

Global Healthcare & Medical Tourism News - Medical Tourism Magazine

Nov 13, 2024
pulisher
Nov 12, 2024

Tourmaline Bio ATM - SVB Leerink

Nov 12, 2024
pulisher
Nov 12, 2024

Varonis Systems, Inc. (NASDAQ:VRNS) Given Average Rating of “Moderate Buy” by Analysts - Defense World

Nov 12, 2024
pulisher
Nov 12, 2024

Tourmaline stock PT nudged by H.C. Wainwright, citing confidence in pacibekitug - Investing.com UK

Nov 12, 2024
pulisher
Nov 11, 2024

Tourmaline Bio, Inc. Reports Third Quarter Financial Results - TipRanks

Nov 11, 2024
pulisher
Nov 11, 2024

Tourmaline Bio (NASDAQ:TRML) Price Target Raised to $49.00 at HC Wainwright - MarketBeat

Nov 11, 2024
pulisher
Nov 07, 2024

Tourmaline Bio Inc (TRML) Quarterly 10-Q Report - Quartzy

Nov 07, 2024
pulisher
Nov 07, 2024

Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights - The Manila Times

Nov 07, 2024
pulisher
Nov 07, 2024

Tourmaline Bio Reports Wider Q3 Loss, $314M Cash Runway Extends to 2027 | TRML Stock News - StockTitan

Nov 07, 2024
pulisher
Nov 05, 2024

AlphaCentric Advisors LLC Sells 69,500 Shares of Tourmaline Bio, Inc. (NASDAQ:TRML) - MarketBeat

Nov 05, 2024
pulisher
Nov 05, 2024

Tourmaline Bio shares get buy rating on IL-6 study optimism - Investing.com Canada

Nov 05, 2024
pulisher
Nov 02, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DICE, Q - GuruFocus.com

Nov 02, 2024
pulisher
Oct 31, 2024

The Best Curling Irons, Based On Several Months Of Testing - Forbes

Oct 31, 2024
pulisher
Oct 31, 2024

Tourmaline Bio to Present at Upcoming Investor Conferences - The Manila Times

Oct 31, 2024
pulisher
Oct 29, 2024

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) Short Interest Update - Defense World

Oct 29, 2024
pulisher
Oct 27, 2024

Short Interest in Tourmaline Bio, Inc. (NASDAQ:TRML) Declines By 20.0% - MarketBeat

Oct 27, 2024
pulisher
Oct 18, 2024

Cantor Fitzgerald Predicts Tourmaline Bio FY2024 Earnings - Defense World

Oct 18, 2024
pulisher
Oct 17, 2024

Tourmaline Bio, Inc. to Post FY2024 Earnings of ($2.85) Per Share, Cantor Fitzgerald Forecasts (NASDAQ:TRML) - MarketBeat

Oct 17, 2024
pulisher
Oct 16, 2024

Tourmaline Bio (NASDAQ:TRML) Shares Up 6.3%Here's What Happened - MarketBeat

Oct 16, 2024
pulisher
Oct 16, 2024

Tourmaline Bio Insiders Placed Bullish Bets Worth US$643.3k - Simply Wall St

Oct 16, 2024
pulisher
Oct 16, 2024

Keros Therapeutics appoints new Chief Medical Officer - Investing.com

Oct 16, 2024
pulisher
Oct 16, 2024

Keros Therapeutics Appoints Yung H. Chyung, M.D., as Chief Medical Officer - GlobeNewswire

Oct 16, 2024
pulisher
Oct 16, 2024

Cantor Fitzgerald Upgrades Tourmaline Bio (NASDAQ:TRML) to Strong-Buy - MarketBeat

Oct 16, 2024
pulisher
Oct 15, 2024

Tourmaline Bio (NASDAQ:TRML) Shares Gap UpStill a Buy? - MarketBeat

Oct 15, 2024
pulisher
Oct 15, 2024

Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024 - The Manila Times

Oct 15, 2024
pulisher
Oct 15, 2024

Palvella Therapeutics Announces Presentations at the 12th Pediatric Dermatology Research Alliance (PeDRA) Annual Conference - The Manila Times

Oct 15, 2024
pulisher
Oct 15, 2024

Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in ... - The Bakersfield Californian

Oct 15, 2024
pulisher
Oct 14, 2024

TRMLTourmaline Bio, Inc. Latest Stock News & Market Updates - StockTitan

Oct 14, 2024
pulisher
Oct 14, 2024

Investing in Tourmaline Bio Inc (TRML): What You Must Know - Knox Daily

Oct 14, 2024
pulisher
Oct 13, 2024

Tourmaline Bio: Looking To Go Beyond FcRn Inhibition With IL-6 Targeting (NASDAQ:TRML) - Seeking Alpha

Oct 13, 2024
pulisher
Oct 13, 2024

Cubist Systematic Strategies LLC Purchases Shares of 37,861 Tourmaline Bio, Inc. (NASDAQ:TRML) - MarketBeat

Oct 13, 2024
pulisher
Oct 13, 2024

Tourmaline Bio (NASDAQ:TRML) Shares Gap Down – Time to Sell? - Defense World

Oct 13, 2024
pulisher
Oct 11, 2024

Tourmaline Bio (NASDAQ:TRML) Shares Gap DownTime to Sell? - MarketBeat

Oct 11, 2024
pulisher
Oct 11, 2024

Guggenheim reiterates Buy on Tourmaline Bio shares, keeps price target By Investing.com - Investing.com UK

Oct 11, 2024
pulisher
Oct 11, 2024

Tourmaline Bio to present research at Cardiometabolic Congress By Investing.com - Investing.com South Africa

Oct 11, 2024
pulisher
Oct 11, 2024

Tourmaline Bio to present research at Cardiometabolic Congress - Investing.com

Oct 11, 2024
pulisher
Oct 11, 2024

Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress - The Manila Times

Oct 11, 2024
pulisher
Oct 11, 2024

Tourmaline Bio announces CMO resignation By Investing.com - Investing.com South Africa

Oct 11, 2024
pulisher
Oct 10, 2024

Tourmaline Bio announces CMO resignation - Investing.com India

Oct 10, 2024

Tourmaline Bio Inc Stock (TRML) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Tourmaline Bio Inc Stock (TRML) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Kulkarni Sandeep Chidambar
CEO
Aug 16 '24
Buy
13.79
5,221
71,998
5,221
MCDADE MARK
Director
Jan 29 '24
Buy
32.50
100,000
3,250,000
448,431
$18.94
price down icon 1.35%
$75.45
price up icon 0.87%
$43.39
price up icon 3.19%
$378.13
price up icon 0.30%
$206.16
price up icon 7.31%
$120.72
price up icon 1.84%
Cap:     |  Volume (24h):